

23

Abstract

24 **Objective:** This study aims to characterize and evaluate the NIH's grant allocation pattern of
25 COVID-19 research.

26 **Design:** Cross sectional study

27 **Setting:** COVID-19 NIH RePORTER Dataset was used to identify COVID-19 relevant grants.

28 **Participants:** 1,108 grants allocated to COVID-19 research.

29 **Main Outcomes and Measures:** The primary outcome was to determine the number of grants
30 and funding amount the NIH allocated for COVID-19 by research type and clinical/scientific
31 area. The secondary outcome was to calculate the time from the funding opportunity
32 announcement to the award notice date.

33 **Results:** The NIH awarded a total of 56,169 grants in 2020, of which 2.0% (n=1,108) were
34 allocated for COVID-19 research. The NIH had a \$42 billion budget that year, of which 5.3%
35 (\$2.2 billion) was allocated to COVID-19 research. The most common clinical/scientific areas
36 were social determinants of health (n=278, 8.5% of COVID-19 funding), immunology (n=211,
37 25.8%), and pharmaceutical interventions research (n=208, 47.6%). There were 104 grants
38 studying COVID-19 non-pharmaceutical interventions, of which 2 grants studied the efficacy of
39 face masks and 6 studied the efficacy of social distancing. Of the 83 COVID-19 funded grants on
40 transmission, 5 were awarded to study airborne transmission of COVID-19, and 2 grants on
41 transmission of COVID-19 in schools. The average time from the funding opportunity
42 announcement to the award notice date was 151 days (SD: ± 57.9).

43 **Conclusion:** In the first year of the pandemic, the NIH diverted a small fraction of its budget to
44 COVID-19 research. Future health emergencies will require research funding to pivot in a timely

45 fashion and funding levels to be proportional to the anticipated burden of disease in the
46 population.

47

48

Introduction

49 The National Institutes of Health (NIH) is the world's largest funder of biomedical
50 research, employing over 20,000 people with a \$41.7 billion budget in 2020 appropriated by
51 Congress.^{1,2} NIH-sponsored research aims to tackle the toughest problems in healthcare while
52 financially supporting research at every stage. Prior research suggested that the NIH research
53 funding has been disproportionately aligned to disease burden in the population.³⁻⁶ Throughout
54 the 1990s, NIH funding patterns were under major scrutiny from Congress and the scientific
55 community due to concerns that funding allocations by the NIH failed to adequately reflect the
56 burden of disease on society.⁵ In 1998, the (IOM) released a groundbreaking report guiding the
57 NIH to improve and develop disease-specific funding processes.²⁰ A landmark study published
58 in the *New England Journal of Medicine* as well as a follow-up study by Gillum et. al in 2011
59 revealed that the NIH disease-specific funding levels were not correlated with several measures
60 of disease burden.^{4,5}

61 The COVID-19 pandemic tested the NIH's ability to fund critical research to answer
62 research questions that significantly affect public health and require urgent scientific clarity. We
63 analyzed the relative weight and composition of the NIH research funding of COVID-19
64 research in 2020 to evaluate the responsiveness of the agency to the pandemic.

65

66

Methods

Study Design and Settings

68 We conducted a cross sectional study using the NIH Research Portfolio Online Reporting
69 Tools Expenditures and Results (RePORTER) datasets of all COVID-19 grants, including grants

70 created by a special COVID-19 appropriations by congress.^{7,8} We also reviewed the NIH Fiscal
71 Year 2020 budget to identify spending on NIH COVID-19 research.⁹

72 We reviewed all grants funded for COVID-19 research between January 1, 2020, and
73 December 31, 2020. For each grant, we collected the date of funding opportunity announcement,
74 award notice date, and the amount awarded as listed in the NIH RePORTER dataset. The date of
75 the Funding Opportunity Announcement was obtained from the NIH COVID-19 grant
76 opportunities.¹⁰

77 We categorized each grant into one of six research types: basic science, clinical science,
78 translational science, public health, infrastructure & education, and other (Appendix 1). Each
79 NIH-funded grant was also subcategorized by clinical/scientific area (Appendix 2). We adapted
80 definitions for research areas and subcategories of primary research subjects from NIH Research,
81 Condition, and Disease Categorization (RCDC) thesaurus and supplemented them using
82 definitions from the Association of American Medical Colleges (AAMC), National Cancer
83 Institute (NCI), Economic Social Research Council, the Department of Health and Human
84 Services (DHHS), and *Methods in Educational Research*.¹¹⁻¹⁷

85 Each grant was independently reviewed and categorized by at least two independent
86 reviewers (LB, SH, CD, CK, AM, BC). For grants that were categorized differently, a study
87 group discussed the aims of the grant and made a final decision.

88

89 *Data Source*

90 RePORTER is an electronic tool developed by the NIH that works in conjunction with
91 the NIH's RePORT website. This tool allows users to generate lists of funded NIH studies based
92 on specific search criteria, such as funding source and research area.⁹ To obtain a list of all the

93 grants that funded COVID-19 research in 2020, we used the NIH's pre-generated COVID-19
94 RePORTER dataset.⁷ The information describing 2020 NIH funding by research was found on
95 the Research, Condition, and Disease Categories (RCDC) RePORTER database.¹⁸

96

97 *Outcomes*

98 The primary outcome for this analysis was to calculate the number of grants and funding
99 the NIH allocated toward COVID-19 in 2020 to the 6 research types and each clinical/scientific
100 area. The secondary outcome was to calculate the time from funding opportunity announcement
101 to award.

102

103 *Statistical Analysis*

104 We calculated the funding amount for research areas by compiling each grant's total
105 funding amount allocated by the NIH. The funding amount for the clinical/scientific area was
106 calculated based on each grant's categorization. We plotted the weekly number of COVID-19
107 grants awarded during 2020. Data cleaning and statistical analyses were conducted using Stata
108 (Version 14.0).

109

110 **Results**

111 In 2020, COVID-19 research accounted for 5.3% (\$2.2 billion) of the annual NIH budget
112 of \$41.7 billion.¹⁹ Of the \$2.2 billion that the NIH spent on COVID-19 research, 86.5% was
113 allocated from congressional special appropriations while the remaining 13.5% of COVID-19
114 funding originated from the regular NIH annual budget that year. We found that several disease
115 and condition-specific research areas were funded at levels much greater than COVID-19 (Figure

116 1). Rare Diseases research received 2.5-fold more funding than coronavirus research and aging
117 research received 2.2-fold more research funding than coronavirus research.¹⁸

118 There were 1,419 NIH COVID-19 grants from the year 2020 in the NIH RePORTER
119 dataset. Of these, we identified 1,108 COVID-19 grants with relevance to COVID-19 research,
120 24 were duplicates appearing in different places and 287 did not have COVID-19 relevance. Of
121 the 1,108 COVID-19 grants identified, 266 grants were able to be matched to their funding
122 opportunity announcement. The average COVID-19 grant was issued funding 151 days (SD:
123 ± 57.9) after its funding opportunity announcement, with a median of 137 days (IQR: 109-196)
124 and range from 43-295 days.

125 In the first three months of the global pandemic, a total of 6 grants were awarded for
126 COVID-19 research. In the first half of 2020, a total of 240 grants were awarded funding (Figure
127 2). Accordingly, in the first three months of 2020, the NIH spent a total of 0.1% of its annual
128 budget on COVID-19 research. In the first half of 2020, the NIH spent 1.2% of its annual budget
129 on COVID-19 research. The months with the most COVID-19 research grants awarded were
130 August and October.

131 Regarding the type of the COVID-19 research funded, basic science research comprised
132 the greatest number of grants funded by the NIH with a total of 313 grants, comprising 6.9%
133 of total COVID-19 research funding. There were 231 grants awarded for public health research
134 and 231 grants awarded for clinical research, accounting for 5.7% and 26.8% of NIH COVID-19
135 funding, respectively. The NIH allocated the largest dollar amount to infrastructure and
136 education research with 55.5% of all COVID-19 funds going to these purposes with 216 grants,
137 accounting for 3.0% of the NIH's annual budget (Table 1).

138 The most common clinical/scientific areas of research were social determinants of health
139 (n=278 grants, 8.5% of COVID-19 funding), immunology (n=211 grants, 25.8% of COVID-19
140 funding), and pharmaceutical interventions (n=208 grants, 47.6% of COVID-19 funding) (Table
141 2). Of the 208 grants dedicated to pharmaceutical intervention research, 85 grants focused on
142 novel therapeutics development (6.4% of COVID-19 funding), 79 grants focused on existing
143 therapeutics (28.2% of COVID-19 funding), and 69 grants on vaccine development (32.2% of
144 COVID-19 funding). Of the 211 immunology grants, 41 grants studied immunity gained after
145 infection of COVID-19, and 15 grants studied immune response from vaccination. Of 64
146 neurological grants, 13 grants focused on changes of tastes or smell.

147 There were 132 grants awarded for COVID-19 testing, comprising 8.5% of all
148 COVID-19 funding. There were 83 grants on COVID-19 transmission, representing 3.5% of
149 COVID-19 funding. Of these, 5 studied airborne transmission and 2 grants studied COVID-19
150 transmission in schools.

151 A total of 104 grants focused on non-pharmaceutical interventions, with 6 grants on the
152 efficacy of social distancing and 2 grants on the efficacy of face masks. Additionally, 92 grants
153 studied the effects of COVID-19 infection in pediatric populations 10 of which examined
154 Inflammatory Syndrome in Children (MIS-C). Geriatric health and COVID-19 was awarded 68
155 grants and maternal health and COVID-19 was awarded 41 grants. There were no grants
156 dedicated to studying the efficacy of face masks in children.

157

158

Discussion

159 Despite the escalating public health threat and poorly-understood mechanism of
160 transmission of the novel coronavirus in 2020, the NIH only spent 5.3% of their total budget that
161 year on COVID-19 research, extending prior literature that that NIH funding priorities
162 misaligned with disease burden in the population.^{5,20} The NIH's slow start in funding COVID-19
163 research was also noted in a February 2021 study in *Health Affairs* by Sampat and Shadlen.⁶
164 They described the current low investment in COVID-19 research as “small compared with the
165 potential value of these interventions for ameliorating or preventing the disease and securing a
166 return to normalcy”. A stronger research effort could have helped reduce transmission of the
167 infection before a vaccine became available.

168 Infrastructure and education accounted for 55.9% of NIH COVID-19 funding, yet many
169 of the major clinical questions surrounding COVID-19 transmission were unanswered at that
170 time, such as transmission among children. Significant restrictions have been placed on the
171 nation's 52 million school-aged children, including school closures, 6-foot distancing
172 requirements, and outdoor masking while distancing; however, only a few grants were dedicated
173 to study these questions in this unique population, creating challenges for evidence-based
174 policymaking.

175 The lack of rapid clinical research funding to understand COVID-19 transmission may
176 have contributed to the politicization of the virus. Some of the most basic questions that were
177 being asked of medical professionals in early 2020, such as how it spreads, when infected
178 individuals are most contagious, and whether masks protect individuals from spreading or
179 getting the virus, went unanswered. In the absence of evidence-based answers to the common
180 questions the public was asking, political opinions filled that vacuum.

181 The social and political climate of the COVID-19 pandemic has been plagued with

204 **Strengths and limitations of this study**

- 205 • Our study characterized and evaluated the NIH's grant allocation pattern of COVID-19
206 research in the year of 2020.
- 207 • We categorized 1,108 grants by research type and clinical/scientific area and identified
208 NIH funding gaps in research dedicated to efficacy of masks and social distancing,
209 airborne transmission, transmission in schools, and COVID-19 in children.
- 210 • We found that in the first year of the pandemic, the NIH diverted a small fraction of its
211 budget to COVID-19 research. Future health emergencies will require research funding to
212 pivot in a timely fashion and funding levels to be proportional to the burden of disease in
213 the population.
- 214 • The type of research and the clinical/scientific areas studied were based on definitions
215 that may not be collectively exhaustive and mutually exclusive.
- 216 • We only reviewed abstracts and did not review the entire funded proposals. There were
217 other barriers to clinical research that were not captured here, including slow institutional
218 review boards and long journal peer-review times.

219 **Patient and Public Involvement**

220 No patient involved in this study.

221 **Contributors:** LB, CD, CMW, and MAM designed the study. LB, CD, AM, SH, CMW, CK,
222 BC, and FM collected the data. LB and CD analysed the data. LB prepared the first draft of the
223 manuscript. LB, CD, AM, SH, CMW, and MAM made critical revisions to the manuscript. All
224 authors reviewed and approved the final draft.

225 **Competing interests:** None declared

226 **Funding:** No Funding was reported for this study.

227 **Data sharing statement:** Data are publicly available.

228 **Ethics statement:** Ethics approval was not sought as the study presents results of an analysis of
229 secondary data and does not involve human participants.

230 **Acknowledgment**

231 We thank Farah Hashim, Jonathan Teinor, and Karashini Ramamoorthi for their contribution in
232 preparing this manuscript.

233

234 Reference:

- 235 1. Baye R. NIH plans to move 3,000 employees to Bethesda campus. Washington Examiner.
236 Published October 17, 2012. Accessed October 13, 2021.
237 [https://www.washingtonexaminer.com/nih-plans-to-move-3-000-employees-to-bethesda-](https://www.washingtonexaminer.com/nih-plans-to-move-3-000-employees-to-bethesda-campus)
238 campus
- 239 2. Frequently Asked Questions. National Institutes of Health (NIH). Published October 31,
240 2014. Accessed October 13, 2021. [https://www.nih.gov/about-nih/frequently-asked-](https://www.nih.gov/about-nih/frequently-asked-questions)
241 questions
- 242 3. Institute of Medicine. *Scientific Opportunities and Public Needs: Improving Priority Setting*
243 *and Public Input at the National Institutes of Health*. National Academies Press; 1998.
244 PMID: 20845560
- 245 4. Gross CP, Anderson GF, Powe NR. The relation between funding by the National Institutes
246 of Health and the burden of disease. *N Engl J Med*. 1999;340(24):1881-1887.
247 doi:10.1056/NEJM199906173402406
- 248 5. Gillum LA, Gouveia C, Dorsey ER, et al. NIH Disease Funding Levels and Burden of
249 Disease. *PLoS One*. 2011;6(2):e16837. doi:10.1371/journal.pone.0016837
- 250 6. Sampat BN, Shadlen KC. The COVID-19 Innovation System. *Health Affairs*.
251 2021;40(3):400-409. doi:10.1377/hlthaff.2020.02097
- 252 7. National Institutes of Health. RePORT. Accessed October 13, 2021.
253 [https://reporter.nih.gov/search/14E9CE024F8FC5D27598B8961CAA4A01A2FFCEB861B](https://reporter.nih.gov/search/14E9CE024F8FC5D27598B8961CAA4A01A2FFCEB861BF/projects?shared=true&legacy=1)
254 [F/projects?shared=true&legacy=1](https://reporter.nih.gov/search/14E9CE024F8FC5D27598B8961CAA4A01A2FFCEB861BF/projects?shared=true&legacy=1)
- 255 8. National Institutes of Health. NIH-Wide Strategic Plan for COVID-19 Research. Published
256 2020. [https://www.nih.gov/sites/default/files/research-training/initiatives/covid-19-](https://www.nih.gov/sites/default/files/research-training/initiatives/covid-19-strategic-plan/coronavirus-strategic-plan-20200713.pdf)
257 [strategic-plan/coronavirus-strategic-plan-20200713.pdf](https://www.nih.gov/sites/default/files/research-training/initiatives/covid-19-strategic-plan/coronavirus-strategic-plan-20200713.pdf)
- 258 9. Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of
259 NIH Funding | grants.nih.gov. Accessed October 13, 2021.
260 <https://grants.nih.gov/policy/natural-disasters/corona-virus.htm>
- 261 10. National Institutes of Health. Funding Opportunities Specific to COVID-19. NIH Grants &
262 Funding. Accessed October 13, 2021. [https://grants.nih.gov/grants/guide/COVID-](https://grants.nih.gov/grants/guide/COVID-Related.cfm)
263 [Related.cfm](https://grants.nih.gov/grants/guide/COVID-Related.cfm)
- 264 11. Basic Science. AAMC. Accessed October 13, 2021. [https://www.aamc.org/what-we-](https://www.aamc.org/what-we-do/mission-areas/medical-research/basic-science)
265 [do/mission-areas/medical-research/basic-science](https://www.aamc.org/what-we-do/mission-areas/medical-research/basic-science)
- 266 12. Definition of clinical research - NCI Dictionary of Cancer Terms - National Cancer
267 Institute. Published February 2, 2011. Accessed October 13, 2021.
268 <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/clinical-research>

- 269 13. RFA-RM-07-007: Institutional Clinical and Translational Science Award (U54). Accessed
270 October 13, 2021. <https://grants.nih.gov/grants/guide/rfa-files/rfa-rm-07-007.html>
- 271 14. Research infrastructure - Economic and Social Research Council. Accessed October 13,
272 2021. [https://esrc.ukri.org/research/future-of-social-science-insights-opportunities-and-
273 expectations/research-infrastructure/](https://esrc.ukri.org/research/future-of-social-science-insights-opportunities-and-expectations/research-infrastructure/)
- 274 15. Lodico M, Spaulding D, Voegtle K. *Methods in Educational Research: From Theory to*
275 *Practice*, 2nd Edition | Wiley. Wiley.com. Accessed October 13, 2021.
276 [https://www.wiley.com/en-
277 us/Methods+in+Educational+Research%3A+From+Theory+to+Practice%2C+2nd+Edition-
278 p-9780470588697](https://www.wiley.com/en-us/Methods+in+Educational+Research%3A+From+Theory+to+Practice%2C+2nd+Edition-p-9780470588697)
- 279 16. Lapinski S. *Research Guides: Participating in Health Research Studies: Types of Health*
280 *Research*. Accessed October 13, 2021.
281 <https://guides.library.harvard.edu/c.php?g=389023&p=2639516>
- 282 17. *Social Determinants of Health - Healthy People 2030* | health.gov. Accessed October 13,
283 2021. <https://health.gov/healthypeople/objectives-and-data/social-determinants-health>
- 284 18. National Institutes of Health. *Estimates of Funding for Various Research, Condition, and*
285 *Disease Categories (RCDC)*. Published June 25, 2021.
286 <https://report.nih.gov/funding/categorical-spending#/>
- 287 19. *FY 2020 By the Numbers: Extramural Investments in Research – NIH Extramural Nexus*.
288 Accessed October 13, 2021. [https://nexus.od.nih.gov/all/2021/04/21/fy-2020-by-the-
289 numbers-extramural-investments-in-research/](https://nexus.od.nih.gov/all/2021/04/21/fy-2020-by-the-numbers-extramural-investments-in-research/)
- 290 20. Institute of Medicine. *For the Public's Health: The Role of Measurement in Action and*
291 *Accountability*. The National Academies Press; 2011. <https://doi.org/10.17226/13005>
- 292

293 **Table 1: NIH Grants for COVID-19 Research by Research Type (2020)**

	Number of COVID-19 Grants (%)	Dollars Spent, USD	Percent of All COVID-19 Funding (%)	Percent of Total NIH Annual Budget (%)
Basic Science	313 (28.25%)	151,252,564	6.85	0.36
Translational	81 (7.31%)	85,436,684	3.87	0.20
Clinical	231 (20.85%)	591,533,574	26.77	1.42
Infrastructure and Education	216 (19.49%)	1,235,403,053	55.92	2.96
Public Health	231 (20.85%)	124,813,879	5.65	0.30
Other	36 (3.25%)	20,946,874	0.95	0.05
Total	1,108	2,209,386,628	100.00	5.30

294
295
296

297 **Table 2: NIH Grants for COVID-19 by Clinical/Scientific Area (2020)***

	Number of Grants	Dollars Spent, USD	Percent of COVID-19 funding, %	Percent of NIH Annual Funding, %
Social Determinants of Health	278	188,229,016	8.52	0.45
Immunology	211	570,461,693	25.82	1.37
Pharmaceutical Interventions	208	1,051,790,057	47.61	2.52
Impacts on Other Disease	133	40,865,572	1.85	0.10
Diagnosis and Testing	132	186,846,477	8.46	0.45
Risk Factor Analysis	111	55,501,547	2.51	0.13
Non-Pharmaceutical Interventions	104	115,971,759	5.25	0.28
Pediatric Health	92	63,635,942	2.88	0.15
Transmission	83	77,675,659	3.52	0.19
Other Research	83	515,823,132	23.35	1.24
Virology	79	33,601,202	1.52	0.08
Geriatric Health	68	467,815,039	21.17	1.12
Neurology	64	21,705,014	0.98	0.05
Pulmonology	61	37,068,124	1.68	0.09
Maternal Health	41	19,633,841	0.89	0.05
Gastroenterology	31	12,081,004	0.55	0.03
Cardiology	18	32,997,172	1.49	0.08
Nephrology	14	8,386,775	0.38	0.02

298 *** Each grant can have multiple areas.**

299

300

301 **Figure 1: NIH Funding by Research Area (2020)**

302

303 **Figure 2. Number of COVID-19 Grants Approved by NIH in 2020**

304

Figure 1: NIH Funding by Research Area (2020)




Figure 2. Number of COVID-19 Grants Approved by NIH in 2020

